EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis.
about
Progress in treatment of ANCA-associated vasculitisSpotlight on rituximab in the treatment of antineutrophil cytoplasmic antibody-associated vasculitis: current perspectivesNovel clinical and diagnostic aspects of antineutrophil cytoplasmic antibodiesCurrent and future prospects in the management of granulomatosis with polyangiitis (Wegener's granulomatosis)Childhood-onset granulomatosis with polyangiitis and microscopic polyangiitis: systematic review and meta-analysisConditions in subjects with rheumatic diseases: pulmonary manifestations of vasculitidesDevelopment of criteria for evaluating clinical response in thyroid eye disease using a modified Delphi technique.Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials.Brief Report: Childhood-Onset Systemic Necrotizing Vasculitides: Long-Term Data From the French Vasculitis Study Group Registry.Clinicopathologic characteristics and outcomes of renal thrombotic microangiopathy in anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis.Coagulation and fibrinolysis index profile in patients with ANCA-associated vasculitis.Efficacy and safety of rituximab as maintenance therapy for relapsing granulomatosis with polyangiitis—a case seriesClassification and characteristics of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort studyImpact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides.The interaction between C5a and sphingosine-1-phosphate in neutrophils for antineutrophil cytoplasmic antibody mediated activation.Epitope analysis of anti-myeloperoxidase antibodies in patients with ANCA-associated vasculitis.ANCA as a predictor of relapse: useful in patients with renal involvement but not in patients with nonrenal diseaseIntravenous immunoglobulin for chronic residual peripheral neuropathy in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome): a multicenter, double-blind trial.Randomized trial of enteric-coated mycophenolate sodium versus mycophenolate mofetil in multi-system autoimmune disease.Urinary levels of high mobility group box-1 are associated with disease activity in antineutrophil cytoplasmic autoantibody-associated vasculitisAssessment of health-related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener's).ANCA positive crescentic glomerulonephritis outcome in a Central East European cohort: a retrospective study.Comparative investigation of respiratory tract involvement in granulomatosis with polyangiitis between PR3-ANCA positive and MPO-ANCA positive cases: a retrospective cohort study.Necrotizing and crescentic glomerulonephritis presenting with preserved renal function in patients with underlying multisystem autoimmune disease: a retrospective case series.Plasma complement factor H is associated with disease activity of patients with ANCA-associated vasculitis.From the nephrologist's point of view: diversity of causes and clinical features of acute kidney injuryDetection of Anti-Pentraxin-3 Autoantibodies in ANCA-Associated Vasculitis.Anti-IgE Monoclonal Antibody (Omalizumab) in Refractory and Relapsing Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss): Data on Seventeen Patients.Association of HLA genes with clinical outcomes of ANCA-associated vasculitisPositron emission tomography scanning in anti-neutrophil cytoplasmic antibodies-associated vasculitis.Different responses to treatment across classified diseases and severities in Japanese patients with microscopic polyangiitis and granulomatosis with polyangiitis: a nationwide prospective inception cohort study.Increased frequency of CCR4+ and CCR6+ memory T-cells including CCR7+CD45RAmed very early memory cells in granulomatosis with polyangiitis (Wegener's).C5a and its receptors in human anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis.Proteinase 3 on apoptotic cells disrupts immune silencing in autoimmune vasculitisEarly Outcomes in Children With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.Cutaneous Ulcers as Initial Presentation of Localized Granulomatosis with Polyangiitis: A Case Report and Review of the Literature.Anti-neutrophil cytoplasmic antibodies in rheumatoid arthritis: two case reports and review of literature.Aberrant cytokine pattern of the nasal mucosa in granulomatosis with polyangiitis.Predictors of relapses in ANCA-associated small vessel vasculitis with kidney involvement.A surprise behind a case of winter vomiting virus
P2860
Q21195258-E5BFF19C-9C65-43E0-BA84-27F57D7A45D2Q26776308-59523860-FE4D-4DDD-A9DE-8640B0E1C6B5Q27000411-F6948913-5341-4A7A-81D4-E91776EEBA2CQ27025692-54422397-D054-427E-85DF-1D68B73248CBQ28069646-2296EFB6-E469-413E-A862-30534F1D844BQ28393792-8ED3CB59-1E2B-49FC-9447-83B866CC37BFQ30413598-7927E63A-98B8-4CD4-8107-BF3815B341E4Q30696868-C4AD2D9C-5449-49F5-AF8F-BA39BB501B53Q30916093-67E7D333-A8E8-4F2D-A3B5-6FBE99EF050FQ33420968-11321A93-6AA4-4E46-84C8-A0B0B0A19749Q33632708-B99C0419-9CF8-4B0A-8370-3845209EAA88Q33757209-B89F118B-81A6-49D4-B87B-3D371D66A4A2Q33767030-10A115B1-AE8F-4327-A07C-47977326764DQ34282077-F3E9B66B-8ADA-4EA7-BA52-408E2B9108E2Q34486205-BC61307E-324F-4EB7-BFCA-8075A797B66FQ34663785-A89B08CA-41FE-44F1-B7F7-16F3B175B2B6Q35124231-1CC47578-BBEC-4353-B6E5-93110EB4554CQ35187840-17953A9C-17CD-4845-819E-40E0577B0823Q35310520-326A8C45-A5AF-4E35-B68C-F7B7463A868CQ35465240-193FF352-E4DE-4EED-9308-40A22F15F729Q35649141-51D3770C-8541-4943-AC97-3F80786D53AAQ35678050-98A2D123-FDA8-45ED-96D9-B3B17AB353C2Q35724221-33F1D03B-2B2A-4C6C-89F7-BE7818E8EB82Q35767701-3A42329F-32C1-43ED-BABF-5107A46D96AAQ35810445-C36E3EB9-6DE4-4298-B891-FDE20483ADF7Q35891577-F941969C-DE46-4F18-AD16-525BC9587D34Q35900660-064A593F-D43F-43C3-9DA7-FED258374C8FQ35946777-D3E70FB0-2FD6-4ADF-AD6C-308650C9D9CAQ36126939-5C5E5A64-F382-45D7-8DAA-E19FB8260BC9Q36152994-7AD37302-C426-4CCC-99CC-406EF7D3C3EBQ36242872-188233F9-F9A2-4E52-9977-FAB612A46360Q36245793-B98DBD26-88EE-491B-8278-A7FAA9E85D8EQ36246112-847F1F9E-A770-4652-8076-2DBD22320620Q36266550-01851D1F-489B-4607-96AD-E47ECB44E0CFQ36332824-C7B7270E-AEAB-4089-BF32-43E6E7566204Q36333104-4881DB1A-DF70-401C-9706-7E6EC191C81DQ36555759-F677EAEC-9F12-4FD5-A123-C74E56AEA18EQ36633133-FCF38A75-3A57-4991-974B-D2C6B32B19B7Q36744892-1BB2E98D-E508-4A77-BD4C-ADF374A975D8Q37077541-554FCEF2-919E-4B50-9F89-466FA8B997D6
P2860
EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
EULAR recommendations for cond ...... ntibody-associated vasculitis.
@ast
EULAR recommendations for cond ...... ntibody-associated vasculitis.
@en
type
label
EULAR recommendations for cond ...... ntibody-associated vasculitis.
@ast
EULAR recommendations for cond ...... ntibody-associated vasculitis.
@en
prefLabel
EULAR recommendations for cond ...... ntibody-associated vasculitis.
@ast
EULAR recommendations for cond ...... ntibody-associated vasculitis.
@en
P2093
P2860
P356
P1476
EULAR recommendations for cond ...... ntibody-associated vasculitis.
@en
P2093
Alfred Mahr
Bernhard Hellmich
David G I Scott
David Jayne
Hasan Yazici
Heiner Raspe
James Witter
Jan Willem Cohen-Tervaert
Loic Guillevin
Oliver Flossmann
P2860
P304
P356
10.1136/ARD.2006.062711
P407
P577
2006-12-14T00:00:00Z